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Paper III. Patients and methods: The sentence “From December 1995 to June 1999 all 
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performed with a time of ethanol exposure of 10 minutes” should be corrected to “From 
December 1996 to June 1999 all sclerotherapy procedures in symptomatic, non-parasitic, non-
neoplastic liver cysts were performed with an ethanol exposure of 10 minutes”.  
 
Paper V. Results, para.3: The sentence “Of the 174 affected individuals, 14 had polycystic 
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and 8.1% of 174 livers containing cysts)”. 
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4. Background  
4.1. Introduction 
The term fibropolycystic disease of the liver encompasses a spectrum of disorders, from 
simple hepatic cysts to more complex entities such as hepatic fibrosis (Table 1). In this thesis 
I have addressed simple hepatic cysts, with or without symptoms. Various terms have been 
used for simple hepatic cysts, such as biliary cyst, non-parasitic cyst of the liver, benign 
hepatic cyst, congenital hepatic cyst, unilocular cyst of the liver, solitary cyst of the liver 1, or 
dysontogenetic liver cyst 2. The term solitary cyst is often inappropriate, since simple (i.e. 
thin-walled, fluid-filled) cysts of the liver commonly present as two or more 1. In the 
following I have used the terms simple liver (or hepatic) cyst(s) for ten cysts or less 3, and 
polycystic liver disease for more than ten cysts. 
Traditionally, symptomatic cysts have been treated by open surgery. During the past two 
decades the less invasive method of laparoscopic fenestration and the even less traumatic 
method of sclerotherapy have been introduced. Because symptomatic liver cysts are rare, little 
has been published about either method and the number of patients is low. To our knowledge, 
random trials comparing sclerotherapy and laparoscopic surgery have not been published. 
However, sclerotherapy has been practised with considerable variation as regards the 
selection of sclerosing agent, the volume of sclerosant applied, the time of exposure of the 
cyst to the sclerosant as well as the use of one single session or multiple sclerotherapy 
sessions. This may explain why the use of sclerotherapy has not gained a wider acceptance. 
Leading liver surgeons have expressed an interest in further research being carried out 
concerning standardisation and simplification of the method of sclerotherapy4;5. 
In this study we have aimed at assessing the short- and long-term effects of procedural 
adjustment, so that sclerotherapy would be more acceptable to the patient and more efficient. 
For example, we have studied the effect of decreasing the number of sessions of ethanol 
injection and the time of ethanol exposure. We also wanted to study the mechanism of 
reaccumulation of cyst fluid. Finally, we wanted to assess the number of patients with 
asymptomatic and symptomastic liver cysts in patients referred to the Radiology Department 
of a Teaching Hospital.  
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Table 1. Fibropolycystic disease of the liver (1) 
________________________________________________________________ 
                Heredity  Patients age         Hepatic pathology 
       at clinical  
       presentation 
___________________________________________________________________________ 
Adults 
Simple hepatic cysts  Not known  40-80 years         Cysts, few 
 
Autosomal dominant  Dominant  30-50 years         Cysts, multiple 
polycystic disease of  
the kidneys with hepatic  
involvement (ADPKD) (2) 
 
Autosomal dominant   Dominant  30-50 years         Cysts, multiple 
polycystic hepatic  
disease without renal 
involvement (ADPLD) 
 
Carolis disease (3)  Not known  Adolescence         Dilated biliary ducts 
and extrahepatic bile     or young adult 
duct cysts (choledochal  
cyst; choledochocele) 
 
Congenital    Recessive  Childhood         Fibrosis  
hepatic fibrosis     or adult         Dilated biliary ducts 
 
___________________________________________________________________________ 
Children 
Infantile   Recessive  3-6 months         Fibrosis 
 
                         Dilated biliary ducts 
Neonatal   Recessive  1 month         Fibrosis 
 
                         Dilated biliary ducts 
Perinatal   Recessive  Birth          Fibrosis 
                 Dilated biliary ducts 
__________________________________________________________________________ 
(1) Modified after Sheila Sherlock6. 
(2) Between 30%7 and 88%8 of patients suffering from ADPKD also have polycystic disease of the liver. 
(3) Carolis disease: Cyst-like dilatation of intrahepatic biliary ducts. Choledochal cyst: Dilatation of extrahepatic 
biliary ducts. Choledochocele:Dilatation of the distal common bile duct localised within the duodenal wall 6. 
 
 
4.2. Embryology 
In 1906, Moschcowitz suggested that non-parasitic hepatic cysts were caused by a 
maldevelopment of biliary ducts during intrauterine life9. At three weeks gestational age, a 
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diverticulum appears at the anterior wall of the foregut. This diverticulum differentiates into 
two parts, one forming the fetal liver and the other forming the extrahepatic biliary tract, 
including the gallbladder 10. The primitive liver cells grow to create sheets of cells. At six 
weeks the first bile ductuli appear within these sheets of cells. At 9-10 weeks intrahepatic 
biliary ductuli appear as a single layer of epithelial cells surrounding the primitive portal 
tracts. At thirteen weeks a second layer or sheet of cells appears. This results in a double 
cylinder, with a slit-like lumen between the layers, as shown in figure 1. This double cylinder 
is the ductal plate 10, named so by Hammar in 1926 11. After thirteen weeks this double plate 
changes its configuration into a network of tubules representing a more advanced stage of 
embryonic bile ducts (figure 1), but still located periportally. Ductal plate malformations exist 
when there are either too few or too many double cylinders 12. Liver cysts and other 
manifestations of fibropolycystic disease of the liver are all the result of an excess of ductal 
plates; on the other hand, in intrahepatic biliary atresia, there are too few bile ducts, since all 
ductal plates have been destroyed 12 .  
The initial ductal plates are observed in the central part of the liver. As the liver develops, new 
ductal plates appear towards the periphery of the liver. As a result of this, early stages of 
ductal plates are present towards the periphery of the liver, while more mature stages are 
located centrally. Therefore, when examining the liver of the fetus, all stages of intrahepatic 
bile ducts are seen, with the more primitive, recently made structures located peripherally. 
Thus, in a diseased organ, the amount of associated fibrosis and the level of biliary duct 
affection will demonstrate different variants of fibrolopycystic disease (Table 1). 
 The production of bile begins at 12 weeks. Adult biliary ductal cells are characterised by 
cytokeratin 19. Fetal biliary ductal cells contain this substance from 9-10 weeks. The same 
cytokeratin is found in the walls of hepatic cysts 13;14 .  
Figure 1. The ductal plate - the 
embryonic bile duct at thirteen 
weeks. 
The embryonic bile duct at thirteen weeks 
has the form of a double cylinder (the 
ductal plate) consisting of two sheets of 
single-layered epithelium surrounding the 
portal vein branches. After thirteen weeks 
the ductal plates change  into a network of 
biliary ductuli.  If this reconstruction does 
not take place, an excess of primitive 
biliary channels (ductal plates) will result 
in fibropolycystic disease (polycystic disease of the liver, Carolis disease or other manifestations). 
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4.3. Genetic aspects. 
While the infantile forms of hepatic fibropolycystic disease are autosomal recessive (Table 1), 
the mode of heritage for the juvenile forms (choledochal cyst and Carolis disease) is 
unknown. The adult form of hepatic fibropolycystic disease includes two variants of 
polycystic liver disease, both following an autosomal dominant heritage. First, polycystic 
liver disease is associated with autosomal dominant polycystic kidney disease (ADPKD). The 
autosomal dominant heritage of ADPKD was demonstrated by Dalgaard in 195715. In 1985 
the first gene for this disease was localised to the short arm of chromosome 1616. Second, 
another variant, autosomal dominant polycystic liver disease (ADPLD) was reported by 
Pirson in 199617. ADPLD is not associated with renal involvement. The prevalence of 
ADPLD in the general population is not known18. In 2000 the gene for ADPLD was localised 
to chromosome 19 by Reynolds 19. The mode of heritage for simple hepatic cysts is not 
known 6. 
 
4.4. Pathology 
Liver cysts are surrounded by a thin fibrous capsule, lined by an inner, single layer of 
cuboidal epithelium20, identical to that found in bile ducts within the portal triads (figure 2). 
When examined immunohistochemically, this epithelium has the characteristics of biliary 
duct epithelium, containing cytokeratin 1913. It shares several properties with the biliary duct 
epithelium, including a response to secretin21.  
In 1918, von Meyenburg described biliary hamartoma as a pathologic entity from which cysts 
in polycystic liver disease develop, designated as von Meyenburg complexes 8;22. These 
complexes, also called microhamartomas, usually measures less than 5 mm6, and consist of 
multiple, small bile ducts embedded in a fibrous stroma. They represent ductal plate 
malformations12, and are associated with fibropolycystic disease23. In a series of 2843 
autopsies, von Meyenburg complexes were found 
in 5.6% of normal livers, in 44% of livers 
containing at least one hepatic cyst, and in 97% of 
livers showing autosomal dominant polycystic 
kidney disease (ADPKD)8.  
Figure 2. This histopathologic image demonstrates the 
wall of a liver cyst covered by a single layered cuboidal 
epithelium, which has evolved from the epithelium of 
aberrant embryonal biliary ductuli. (Courtesy of Ole Johan 
Halvorsen, MD, Department of Pathology, Haukeland 
University Hospital) 
 
  15
4.5. Epidemiology 
Simple, asymptomatic cysts are the most frequently occurring focal liver lesion, with a 
reported prevalence varying between 1% in autopsies24 to 2.5-18% when based on imaging25-
27. These are seldom diagnosed before the age of 40 years, after which the prevalence 
increases gradually with age27, without significant differences between the sexes27. Polycystic 
liver disease is less frequent than simple hepatic cysts, but the prevalence of polycystic liver 
disease as well as of simple hepatic cysts in the general population is not known. That there 
are at least two different definitions of polycystic liver does not make the investigation of this 
topic easier18. The majority of patients presenting with polycystic liver disease suffer from 
autosomal dominant polycystic kidney disease (ADPKD) with a reported prevalence of 
0.1%28. The occurrence of liver cysts in ADPKD vary from 30 to 88% in different 
studies7;8;29.  
Since the occurrence of symptomatic liver cysts is low, true population-based data are sparse. 
A report from Sanfelippo in 1974, based on 88 000 explorative laparotomies, revealed 
symptomatic liver cysts in 0.2% of the cases30. Between 80 and 90%31;32 of symptomatic liver 
cysts, both polycystic and simple, occur in women31;32. The reason for this is unclear, but 
gestational hormones33 and estrogen may play a role34. Women who have never been pregnant 
and who have not used estrogen medication have a lower statistical risk of symptomatic 
hepatic cysts in autosomal dominant polycystic renal disease35.  
 
4.6. Symptoms 
 
Simple liver cysts only rarely cause acute abdominal symptoms. When this occurs, it is due to 
spontaneous or traumatic rupture, to hemorrhage into hepatic cysts36, or to torsion of an 
exophytic cyst or secondary infection. The most common symptoms are chronic pain, 
abdominal mass and early satiety due to compression of the stomach, although jaundice and 
respiratory problems have also been reported 37-44. When chronic, even moderate symptoms 
may result in a permanent reduction in the patients’ quality of life.  
In polycystic liver disease, symptoms may be severe when the degree of hepatomegaly is 
extreme45;46. Such symptoms are: lower extremity edema due to inferior vena cava 
compression; ascites secondary to hepatic venous outflow obstruction; portal hypertension 
with esophageal varices; severe nutritional problems due to compression of the stomach and 
gastrointestinal tract; and severely reduced quality of life47;48. 
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Several case reports have been published on cystic disease of the liver complicated by 
malignancy such as adenocarcinoma 49, squamous cell carcinoma 50 and cholangiocarcinoma 
51;52. It has been claimed that there is an association between polycystic liver disease and 
cholangiocarcinoma 51. According to one author, the most frequent complication in autosomal 
dominant polycystic liver disease with renal involvement is the infection of liver cysts, with 
cholangiocarcinoma as the second most frequent complication 28. 
 
4.7. Diagnosis  
The diagnosis of liver cysts is based on cross-sectional imaging, including ultrasound (US), 
computed tomography (CT) and magnetic resonance imaging (MRI). The main differential 
diagnoses are pyogenic abscess, amoebic abscess, hydatid cysts and necrotic neoplasm 53.  
 
 
 
Figure 3. Ultrasound of the liver showing a 
simple, thin-walled cyst with anechoic 
contents and posterior echo enhancement.   
 
 
 
Ultrasound (US) has been known for its 
great potential in differentiating cystic 
abdominal  lesions from solid ones since the early period of US technology53-60. US has been 
the method of choice for investigating the liver for about three decades55;55;59;61-67;67A high 
spatial resolution enables a detailed characterization of liver cysts68. The sonographic criteria 
of a cyst are a thin, not discernable wall, anechoic cystic contents and posterior echo 
enhancement (figure 3). Based on these critera, high diagnostic accuracy has been reported 
66;69-71. The major limitations of US occur in obese patients and in patients with severe 
deformities, such as kyphoscoliosis.   
 
Computed tomography (CT). The CT-criteria for a simple liver cyst include a lesion 
containing homogenous fluid with a density of 0-10 Hounsfield Units (HU), surrounded by a 
thin, not discernable, non-enhancing capsule3;59;63;72;73 (figures 4 and 5). When these criteria 
are used, the diagnostic accuracy is high. However, statistical data are limited, since studies 
on the diagnostic efficacy of CT in diagnosing liver lesions are focused on malignant disease. 
A sensitivity greater than 90% in the detection of liver metastasis with diameters greater than 
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10 mm has been reported74-79. When CT findings are equivocal, US63or MRI79 are utilized to 
distinguish cystic lesions from solid ones. In cases of patchy capsular enhancement or a 
thickened capsule, neoplasm or abscess is the more likely diagnosis. After a haemorrhage into 
a cystic cavity, CT may show high attenuation consistent with blood clots for 1-3 days 
following the event. In these cases, CT is more accurate than US. 
Because CT, US and MRI alone are unable to differentiate between a simple liver cyst and a 
hydatid cyst, additional tests have to be performed if hydatid disease is suspected 80. 
 
 
 
 
Figure 4. 
CT scan demonstrating a large liver cyst with a thin 
wall and homogenous contents.  
 
 
 
 
 
Figure 5  
CT scan showing multiple liver cysts in  
polycystic liver disease.  
 
 
 
 
 
Magnetic Resonance Imaging (MRI). Similar to CT, the MR-criteria for liver cysts include 
a thin, non-enhancing wall, not discernable from the surrounding liver tissue (figure 6). On 
T1- and T2-weighted images a liver cyst returns a low and a high signal, respectively63;81. In a 
recent study 79of  candidates for liver resection, MRI was superior to CT in diagnosing cysts 
with diameters less than 10 mm. Nine cysts characterized as malignant or indeterminate by 
CT were all correctly characterized as cysts by MRI. MRI was thus the superior method for 
the staging of malignant disease of the liver79. When a hemorrhagic cyst represents a 
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diagnostic problem on US and CT, MRI may provide characteristic diagnostic 
information3;63;82. 
 
Figure 6. Axial T1- weighted MRI in a 56-year-old female 
with policystic liver disease. High intensity liver- lesions 
are consistent with cysts containing haemoglobin or 
haemoglobin degradation products. Low-intensity lesions 
represent cysts containing ordinary cystic fluid.  
 
4.8.Treatment of liver cysts 
Indications for treatment are chronic symptoms which lead to a general reduction of the 
quality of life, such as hepatomegaly, pain, local bulging, early satiety due to compression of 
the stomach, biliary duct compression, as well as acute abdominal symptoms caused by cystic 
rupture or hemorrhage into the cyst. Traditionally, surgery has been the method of choice for 
symptomatic liver cysts45;46. During the past two decades, two different percutaneous methods 
have been described: laparoscopic fenestration5;80 and percutaneous sclerotherapy31;32;83;84.   
 
4.8.1. Surgery   
The alternative surgical methods for treating symptomatic liver cyst are fenestration, liver 
resection and liver transplantation. 
Fenestration (also termed de-roofing) is the surgical method most commonly used today, and 
consists of making an opening - a fenester or window - in the cyst. Thereafter the cystic fluid 
is drained into the peritoneal cavity from which it is resorbed and subsequently eliminated via 
the urine. This method can be performed laparoscopically. Some publications report 
favourable results of laparoscopic cyst fenestration both of simple cysts 5;80;85 and polycystic 
liver disease 86.However, this number of studies is few. In addition, the quantity of patients in 
each study is low, and the times of observation are short5. Nor have random studies 
comparing different surgical methods with sclerotherapy been carried out5. In order to prevent 
recurrence, laparoscopic fenestration has been combined with the use of an omental 
transposition flap 87. Others have used a combination of laparoscopic fenestration and ethanol 
sclerotherapy 88;89. Only after the failure of laparoscopic fenestration should open surgical 
fenestration or other surgical methods be used. Fenestration performed in open surgery 
combined with liver resection is usually only appropriate in severe cases of polycystic liver 
disease45;46. 
Until recently, Liver resection has been the traditional surgical method for symptomatic liver 
cysts. In solitary or few cysts, partial or total cystectomy and more infrequently formal 
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hepatic resection was performed. The recurrence rate following partial cystectomy has been 
reported as from 0 to 37 % 4. In polycystic liver disease, surgical treatment may be indicated 
when severe hepatomegaly reduces the quality of life severely or when complications such as 
jaundice occur, due to compression of biliary ducts 90. In the largest series published on liver 
resection combined with fenestration the mortality and morbidity rates rate were 3% and 58%, 
respectively. This report involved severe cases of polycystic liver disease46. 
Liver transplantation is a high risk and high cost procedure with a mortality ranging from 0-
20%4;48;91-94. For patients who survive and avoid severe postoperative morbidity, great 
improvement of the quality of life may be achieved 29;48;93;95. Lifelong immuno-suppressive 
treatment may be necessary 4. 
 
From a surgical point of view, polycystic liver disease may be subdivided into three 
categories: Type I, Type II and Type III 4. In Type I, there are a few large cysts, well suited 
for laparoscopic fenestration as well as for sclerotherapy. Although the results of liver 
resection or total cystectomy for Type I polycystic disease are good, with postoperative 
morbidity of only 10%, few recurrences and only one postoperative death reported4, the 
procedure of choice should be sclerotherapy5.  
In Type II polycystic liver disease, some segments of the liver are relatively free of cysts 
while others are diffusely involved, with large numbers of small cysts. If at least two adjacent 
liver segments are relatively free of cysts, surgery is worth considering. Liver resection 
combined with fenestration of multiple cysts is the method of choice. The reported 
peroperative mortality has been 0-20%4, whereas postoperative morbidity may be as high as 
50% 4.  
In Type III polycystic liver disease, hepatomegaly is due to innumerable small cysts involving 
all of the liver segments, and liver tranplantation may be the only therapeutic alternative 
29;48;93;95. 
 
 
4.8.2. Percutaneous interventional procedures.  
The alternative methods are aspiration without or with sclerotherapy, using ethanol or other 
sclerosing agents. In 1983, Saini reported on 15 sole aspiration procedures on liver cysts in 13 
patients. Within two years, all cysts had regained their original size 96. Some cysts recurred 
within two weeks. The exact interval before recurrence was not noted, but it became clear that 
cysts may recur rapidly following aspiration alone. If the symptoms disappeared after 
  20
aspiration and reappeared when the cyst recurred, surgery was considered necessary. This 
diagnostic procedure was initially used therapeutically, but still has considerable value  
in deciding whether to perform sclerotherapy.  
 
Sclerotherapy.  
In 1976, Goldstein97, having been inspired by the work of Vestby98;99 on sclerotherapy of 
renal cysts by means of panthopaque, injected panthopaque in a large, symptomatic liver cyst. 
Although Goldstein’s results were promising with no recurrence after eight or 16 months, no 
further work on sclerotherapy using panthopaque has been published. The first paper on liver 
cyst sclerotherapy using ethanol was published by Bean in 1985 84. He reported a good 
response to sclerotherapy of six cysts in six patients. His work was followed by others, who 
reported high success rates ranging from 70 to100% using differing procedures (Table 2). 
Anderson 83, vanSonnenberg 32 and Furuta100 used multiple-session procedures, while other 
authors used a single-session procedure 101. Moreover, the time of exposure to ethanol varied 
considerably among different authors. Although the results were promising, the method did 
not gain general acceptance among liver surgeons. In a review of the literature5 concerning  
nearly all studies on ethanol sclerotherapy31;32;83;84;101-105 and laparoscopic surgery85;87;106-114 
published in English until 2001, the authors concluded that ethanol sclerotherapy probably 
was as effective as laparoscopic fenestration, having the advantage of fewer complications. 
They also concluded that a random controlled trial comparing ethanol sclerotherapy with 
laparoscopic surgery would be ideal, but that such a study would be difficult to conduct since 
symptomatic simple cysts are rare and long-term follow-up would be necessary5.  
The use of minocycline hydrochloride as a sclerosing agent has been reported in three studies 
115-117. A total of 15 patients were treated for simple hepatic cysts. The results were promising, 
but the number of patients is limited, and further clinical research is necessary.  
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Table 2. Ethanol sclerotherapy of benign liver cysts:  
data from several different authors. 
___________________________________________________________________________________ 
Author  Cysts /  Sessions Time of  Maximum  Success 
  patients per  exposure alcohol rate (%) 
Year    cyst  (minutes) volume(ml)  
______________________________________________________________________ 
Bean   6/6  1  20  200  100 
1985     
Kairaluoma 15/8  1  60  100    100 
1989 (1)    
Andersson  9/9  1-8  10-20  100  89 
1989     
Simonetti 30  1?             20-30  20-30% 70 
1993                                                                                      of cyst vol. 
Montorsi 21/21  ?   20-30  25%  72 
1994                                                                                      of cyst vol. 
vanSonnen- 14/ (2)  1 –11 (3) 20 -–0  33-50% 88 
berg 1994         of cyst vol. 
Tikkakoski 59/25  1  60  100  97 
1996 (1)     
  
(1) The study published by Tikkakoski was carried out at the same institution (Oulu University 
Hospital, Finland) and includes the same patients as the study published by Kairaluoma. 
Tikkakoski added patients treated during the period 1987- 1992. Both of these authors applied 
100ml alcohol for 20 minutes 3 times (3 times 100ml for a total of 60 minutes) in cyst with 
volumes over 1000 ml.  
 
(2) In vanSonnenbergs’ study, 24 cysts in 20 patients were treated: 14 cyst with alcohol alone, 10 
cysts with tetracycline, doxycycline or a combination of alcohol and tetracycline or doxycycline.  
 
(3) Using the multiple session procedure, one single cyst was treated by 11 different sessions 
corresponding to 11 doses of ethanol (33-50% of cyst volume x 11), and a cumulated time of 
exposure to ethanol of 330 minutes during 44 days of catheter drainage. 
 
 
In the treatment of polycystic liver disease, the comparative roles of ethanol sclerotherapy and 
laparoscopic surgery have not been clarified in the review study5. The use of laparascopic 
fenestration in these patients was limited. Another study86 has concluded that although the 
exact role of laparascopic cyst fenestration in the treatment of polycystic liver disease remains 
unclear, the method appears to be of benefit to a limited, selected number of patients. In this 
study, this therapy is recommended in massive hepatic cystic disease when the cysts are not 
well suited for percutaneous sclerotherapy.  
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Only a few case reports have been published regarding the use of ethanol sclerotherapy in the 
treatment of multiple medium and large size cysts in polycystic liver disease 118;119. More 
research is needed to explore this problem.    
 
 
5. Aims of the study 
To examine the short- and long-term effect of single-session ethanol sclerotherapy on the size 
of benign liver cysts; 
 
-to examine the effect of single-session ethanol sclerotherapy on benign liver cysts performed 
with a short exposure (10 minutes) of the cyst wall to ethanol; 
 
-to evaluate the results of single-session ethanol sclerotherapy of benign liver cysts on the 
patients symptoms; 
 
-to examine the cystic contents before and after ethanol sclerotherapy by cytologic and 
biochemical methods in order to investigate the post- sclerotherapy re-collection of fluid 
within the cysts; 
 
-to examine the occurrence of symptomatic and non-symptomatic hepatic cysts in a 
University Hospital patient population. 
 
6. Material and methods  
6.1. Patients 
 
The present work consists of two major study groups, one consisting of 28 patients with 
symptomatic liver cysts (Part I, Papers I-IV) and one consisting of 1541 consecutive patients 
referred for diagnostic ultrasound examination of the abdomen (Part II, Paper V).  
 
6.1.1.Patients. Part I.  
A total of 28 patients (24 females and 4 men) aged 33-83 (mean 67) years, admitted to the 
surgical outpatient clinic at Haukeland University Hospital (HUS) for various symptoms 
related to liver cysts, were included in the study during the years 1993-2002. Data on patients 
and the Paper in which they appear are listed in Table 3. 
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Table 3. Patients with simple (S) or polycystic liver cysts (P) included in papers I-IV treated 
by ethanol sclerotherapy during the period from March 1993 to November 1999 and from 
May 2002 to September 2002. Patients listed twice or more had more than one cyst treated. 
 
                        
Patient   Type Sex/ Date         Included             Time of           Cyst    Final volume/ 
number    of age (month        in paper          exposure           volume            Time of observ    
                 cyst       year)                            (minutes)            (ml)                (ml/months) 
__________________________________________________________________________________________
               
 1 S F  71 3 / 93  I, II  7         1752        0 / 67 
 2 S F  63 2 / 94  I  20         4800   959 / 7 
 3 S F  74 3 / 94  I,II  20         275       0 / 54 
 4 S F  82 4 / 94  I,II  8         2000       0 / 53 
 5         P F  38    5 / 94  I  20         680      29 / 8 
 6 P F  33     1 / 95  I,II  20         200       0 / 43 
 7 S F  76 3 / 95  I,II  20         450       0 / 42 
 8 P F  40   3 / 95  I,II  20         210     42 / 12 
 9 P M 69    3 / 95  I,II  10         2700   188 / 41 
 10 P F  61    8 / 95  I,II  20         680     21 / 36 
 11 S F  73 2 / 96     II  20         2418       0 / 30 
 12 S F  75 8 / 96     II  20         2000       0 / 24 
 13 S F  60 12 / 96     II, III  10         1800     35 / 47 
 14 S F  46 1 / 98          III  10         394             4 / 37 
 15 S F  61 2 / 98          III  10         30              0 / 32 
 16 P F  44    4 / 98          III  10         1920   523 / 31 
 16 P F  44    5 / 98          III  10         390              0 / 29 
 17 S F  58 9 / 98          III  10         330                     0 / 13 
 18 P F  58    5 / 99          III  10         840          139 / 17 
    18 P F  58    6 / 99          III  10         110              8 / 16 
 18 P F  58    6 / 99          III, IV 10         167           85 / 16 
 19 S M 58 6 / 99          III  10         4110      86 / 14 
    16 P F  45   6 / 99                IV *) ----         ----                      ---- 
 20 S F  62 8 / 99                IV ----         ----                      ---- 
 21 S F  77 10 / 99                IV ----         ----                      ----  
 22 S F  71 11 / 99                IV ----         ----                      ---- 
 23 S M 83 11 / 99                IV ----         ----                      ---- 
 24 P F  56    5 / 02                IV ----         ----                      ---- 
 25 P F  67    6 / 02                IV ----         ----                      ----  
 26 P F  53   6 / 02                IV ----         ----                      ----  
 27 P F  40    6 / 02                IV ----         ----                      ---- 
    28 S M 86 9 / 02   IV ----         ----                      ----  
__________________________________________________________________________________________ 
  
   *  Study IV did not involve data on time of exposure for each cyst, cyst volume or time of observation.          
 
In cases of equivocal abdominal symptoms, a positive aspiration test was required before 
inclusion. All aspiration tests were performed by an experienced radiologist. A positive test 
was defined as the disappearance of abdominal symptoms after the evacuation of the cyst.  
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The criteria for inclusion in the study were cyst-related symptoms as judged by an 
experienced gastrointestinal surgeon and one or more symptomatic liver cysts diagnosed by 
imaging. 
The criteria for exclusion from the study were: hydatid cyst; neoplastic cyst; cyst-like ectasies 
of the intrahepatic biliary ducts (Carolis disease); coagulopathy; or polycystic liver disease 
with innumerable small cysts but without large or medium-size cysts suitable for 
sclerotherapy.  
After contrast injection and before the instillation of ethanol, the following three criteria had 
to be met: 1) no communication between the cyst and the biliary tree; 2) no intraperitoneal 
leakage of contrast; 3) the ability to aspirate the contrast from the cystic cavity.  
Informed consent concerning ethanol sclerotherapy was given by all patients.  
 
6.1.2. Patients, Part II                                                
A total of 1541 patients (869 females and 672 males), aged 0-99 (mean 57.7) years, referred 
for abdominal ultrasound to the Department of Radiology, Haukeland University Hospital 
were included during the period 21 January 2000 to 11 November 2000. A referring 
Department was registered for 1240 of the patients: 404 patients from the Department of 
Oncology (all patients had either active or healed malignant disease); 290 patients from the 
Department of Internal Medicine; 243 patients from the Department of Surgery; 100 patients 
from the Department of Paediatrics; and 243 patients from other departments (Departments of 
Neurology, Dermatology, Rheumatology, Psychiatry and Emergency).   
 
6.2. Methods - Part I. 
6.2.1. Study design.  
Part I was a prospectively conducted, observational and experimental study. The clinical 
examinations prior to inclusion were done by an experienced gastrointestinal surgeon, who 
classified symptoms as mild, moderate or severe. Pre-procedure liver function tests were 
taken. If there was no suspicion of liver tissue damage at that time, these tests were not 
repeated at clinical follow-up. To investigate the short- and long-term effect of 20 minutes 
exposure to ethanol, 13 patients were studied (Papers I and II), and to investigate the effect of 
10 minutes exposure to ethanol, 7 patients were studied (Paper III). To investigate the 
cytologic and biochemical aspects of ethanol sclerotherapy, 11 patients were studied (Paper 
IV).  
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6.2.2. The effect of sclerotherapy. 
The effect of sclerotherapy was evaluated by the measurement of the pre-and post-procedure 
cyst volume, by the registration of symptoms and through laboratory tests. 
 
Measurements of cyst volume.  
The cyst volume on the day of sclerotherapy was measured by direct measurement of the 
aspirated cystic contents. Measurements of cyst volume was performed using CT and the 
formula: V = d1 x d2 x d3 x 0.523 before sclerotherapy and at follow-ups scheduled at 3, 6, 
12 and 24 months. This method has been applied to uterine and ovary volume measurement 
using ultrasound120.  
 
Clinical evaluation of symptoms, and laboratory tests.  
The patients were seen at an outpatient clinical consultation scheduled at 3 and 6 and 12 
months after sclerotherapy. The symptoms were classified as improved, unchanged or 
deteriorated at each follow-up. The following liver function tests were taken before 
sclerotherapy: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl 
transpeptidase (GT), bilirubin, and alkaline phosphatase. Also hemoglobin, thrombocytes, 
cephotest and INR were taken. A test for hydatid disease was taken before sclerotherapy when 
this diagnosis was suspected.  
 
Evaluation of side effects.  
 
Procedural pain was evaluated by the radiologist during the procedure, and classified as 
absent, mild, moderate or severe. During our early work with ethanol sclerotherapy we tested 
for increased blood ethanol concentration one hour after the sclerotherapy procedure. The 
routine use of this test was discontinued due to low values of ethanol and absence of clinical 
signs of ethanol intoxication. We later determined ethanol intoxication by constantly 
evaluating the patients’ apprehension and level of conciousness. Therefore, a specific ethanol 
measurement was only made if there was suspicion of ethanol intoxication based upon clinical 
evaluation, or if large cysts requiring the largest volume of ethanol were treated, particularly 
if the cyst wall was in close contact with large vessels. 
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Etiology of cystic fluid reproduction after sclerotherapy 
 
To investigate the etiology of the re-filling of the cystic cavity, the cystic fluid of 11 cysts in 
11 patients was examined on the day of sclerotherapy and 2-8 days (mean 4.5) later and 
analysed for cytologic and biochemical parameters. These eleven patients represented all 
patients referred for sclerotherapy during two periods, the first period from September 1998 to 
November 1999 and the second from May 2002 to September 2002. Two cysts were 
examined only by biochemical methods, since too many erythrocytes disturbed the cytologic 
examination. As a result, nine cysts were examined by cytologic methods and eleven cysts by 
biochemical methods.  
The cytologic examination was made by qualified technologists using a manual semi- 
quantitative method by which the percentages of the different cellular components could be 
calculated. The biochemical analysis included CRP, orosomucoid and haptoglobin indicating 
acute inflammatory reaction, protein and albumin indicating capillary permeability, and 
bilirubin and alkaline phosphatase as indicators of cystic epithelial function. 
In the last five patients, examined in 2002, blood was analysed for the same biochemical 
parameters on the day of sclerotherapy. The second blood sample was taken 2-3 days (mean 
2.2) after sclerotherapy.  
 
6.3. Sclerotherapy procedure    
The patients were admitted to the hospital either the day prior to or early in the morning of the 
day the procedure was scheduled. For the first 22 patients, a premedication consisting of  50-
100 mg pethidine and 0.6 mg atropine i.m.was administered 30-45 minutes before the start of 
the procedure and supplementary i.v.pethidine injections were given during the procedure if 
required. For the last 5 patients a different method of analgesia was used. This method 
differed in that an anesthetic nurse was present throughout the procedure, and no 
premedication was given. Sedation was achieved by midazolam (Dormicum; Roche) and pain 
control by means of short-term analgesics, usually alfentanil (Rapifen “Janssen-Cilag”), and 
more infrequently ketamin (Ketalar “Pfizer”), given intravenously during the procedure 
according to the individual patient’s needs. 
The patient was placed on an angiographic table and the local anesthetic lidocaine 10mg/ml 
(Xylocain “Astra Zeneca”) was administered. Figures 7, 8A and 8B show the equipment used 
for the sclerotherapy procedure. Under ultrasound guidance, the needle tip was inserted into 
the cyst. An 18G, 20 cm needle  (COOK , catalogue number SDN- 18- 20 -T ) was preferred.  
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Puncture was made through 1-3 cm of liver tissue in order to reduce the possibility of leakage 
from the cyst. Thereafter a 90 cm Amplatz super stiff guide wire (MEDA, Amplatz extra stiff, 
90 cm, catalogue number 1140 35 090) was introduced well into the cyst, initially under 
ultrasonographic guidance, and immediately after under fluoroscopic control (fig 7). A 7F 
dilator was used if necessary to reduce resistance, particularly in intercostal punctures. 
Thereafter a 7F, 30 cm pigtail catheter (Catalogue number 711007 030, PBN Medicals, 
Denmark) was inserted as far as possible into the cyst.  
 
 
 
 
 
 
Figure 7. Equipment for the sclerotherapy 
procedure. An 18 g (1.2 mm ) 20 cm long needle 
(1) is inserted under ultrasound guidance. The guide 
wire (2) is passed through the needle into the cyst. 
The needle is removed. A 7F dilator (3, yellow) is 
pressed through the abdominal wall.  Next the 7F 30 
cm long pigtail catheter (4) is introduced and 
connected with a drainage bag (5). 
 
 
 
 
 
 
 
 
 
 
Figure 8A. Sclerotherapy procedure in the 
interventional radiology laboratory. The patient is 
placed on the angiographic table. Equipment for 
ultrasound-guided puncture combined with 
fluoroscopy-guided procedure is present.. Cysts with 
volumes greater than 1000 ml are drained using an 
angiographic injector as illustrated in  this figure. 
 
 
 
 
 
 
Figure 8B. 
Cystic fluid is aspirated from the patient into the 
injector. When the syringe is full, the three way 
stopcock (arrow) is rotated, and the fluid is 
injected into the drainage bag. Thereafter the three 
way stopcock is rotated again to drain cystic fluid 
from the patient into the injector and so forth. 
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After emptying of the cyst, contrast (Omnipaque 300 mg J/ml mixed with an equal volume of 
saline) corresponding to about 50% of the cyst volume was injected. Radiographs were taken 
with the patient lying in three different body positions, to determine contra-indications such as 
communication with the biliary ducts, leakage of contrast into the peritoneal cavity, or 
problems related to aspiration of the injected contrast. Figure 9 is a radiograph of a liver cyst, 
demonstrating communication between cyst and biliary ducts visible at contrast injection. 
Sclerotherapy was therefore contra- indicated in this patient. 
 
 
 
 
Figure 9. Injection of contrast into the cystic cavity. 
The cyst has been evacuated, and contrast has been 
instilled via the catheter. When ductal branches are 
filled with contrast – as was the case in this patient – a 
communication between the cyst and the biliary ducts 
was present, and the procedure was aborted. 
 
 
 
 
 
 
After aspiration of the contrast, 96% ethanol was injected. The volume of ethanol ought to be 
10 per cent of the cyst volume, but should never be more than 100 ml. The patient’s position 
was slowly changed from supine to prone in clockwise and anti-clockwise directions a few 
times during the procedure to ensure contact between ethanol and every aspect of the cystic 
wall.  Ethanol was left within the cyst for 10 minutes and then evacuated. In Papers I and II a 
new dose of the same volume of ethanol was injected once again - for another 10 minutes - 
during the same session. Thus, the total time of exposure to ethanol was 20 minutes, except 
for three patients (patients 1, 4 and 9 in Table 3). These three patients were exposed to ethanol 
for only 7, 8 and 10 minutes respectively because the procedure had to be shortened due to 
pain. In Paper III only one single dose of ethanol was given for 10 minutes. The volume of 
ethanol was the same: 10 per cent of the cyst volume, but never more than 100 ml. 
Catheter- position was repeatedly controlled by fluoroscopy throughout the procedure. All 
ethanol was evacuated. The catheter was thereafter removed during continuous aspiration. 
However, this part of the procedure was changed after one patient experienced severe pain of 
long duration following the procedure (patient 3, Table 3) most likely due to localised 
chemical peritonitis caused by ethanol leakage during catheter withdrawal. Since then, we 
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irrigated the cyst with saline after aspiration of all ethanol. Saline was thereafter aspirated and 
the catheter removed, thus avoiding the leakage of ethanol into the peritoneum.  
After the procedure the patient rested in bed for 4 hours. During our initial years of 
sclerotherapy all patients were hospitalised for at least 24 hours. Later, patients were usually 
able to leave the hospital the same evening, if symptoms were minimal. 
  
Methods - Part II. 
 
Study design – method: 
Part II was a prospective, cross-sectional study. The ultrasound examinations were performed 
by  24 physicians (eight consultants, 16 residents) with experience in US varying from one to 
20 years. A Toshiba Power Vision 7000 or an ATL HDI 5000 was used for adults, while 
children were examined using an ATL HDI 5000 machine. All the units were equipped with 
curved array and phased array sector multifrequency transducers. The ATL HDI 5000 
ultrasound machine was equipped with three transducers used for examination of the liver. 
The transducer most commonly used had a curved array design and a frequency range of 2.0–
5.0 MHz. The second transducers also had a curved array design, but with a frequency range 
from 4.0–7.0 MHz, suitable for small individuals and children, and one minicurved transducer 
with a frequency range from 2.0-4.0 MHz. The Toshiba PowerVision 7000 ultrasound 
machine was equipped with one curved array and one minicurved transducer, both with a 
frequency range of 3.0-6.0 MHz. All transducers of both machines were equipped with 128 
piezo-electric crystals. 
 
Criteria for a cyst were: focal liver lesion with anechoic contents; thin wall not distinguishable 
from the adjacent liver tissue; and posterior acoustic enhancement. The presence or absence 
of liver cysts was continuously recorded in a protocol at the ultrasound laboratory, and further 
details with regard to diameter and number of cysts were recorded in the radiology report. 
When the measurement of cyst diameter did not appear in the report, it was measured on the 
ultrasound images by the investigator.  
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6.3. Statistics   
Differences in cystic volumes before and after ethanol liver cyst sclerotherapy were examined 
using the Wilcoxon Signed Ranks Test for non- parametric data (papers II-IV). Differences in 
cystic volumes before and after sclerotherapy according to time of exposure to alcohol (10 vs. 
20 minutes) were examined using a non-parametric test for comparison of two groups (Mann- 
Whitney test). In Paper V the association between gender and the occurrence of cysts was 
examined using Fisher's exact test and logistic regression analysis. The ability of senior 
examiners and residents to diagnose liver cysts was tested using Fisher’s exact test. The 
association between the occurrence of cysts, age of the patients and referring department was 
examined using logistic regression analysis. 
 
7. Summary of results    
Paper I.  
During the period from March 1993 to August 1995, ten cysts in ten patients were treated 
using single-session ethanol sclerotherapy. After a mean observation time of 17.3  (7.8 - 42.0) 
months, the volumes of the cysts had decreased from a mean volume of 1375 (200 - 4800) ml 
to a mean volume of 126 (0 - 966) ml. This represents a mean volume reduction of 90.8 (77 - 
100) %. In eight cysts, post-procedural re-accumulation of cystic contents was observed, but 
here too there was a satisfactory volume reduction some time later.  
By protocol the cysts were supposed to be exposed to ethanol for 20 minutes, but due to pain 
the time of exposure was reduced to 7, 8 and 10 minutes, respectively in three patients 
(patients 1,3 and 9 in Table 3). Even though these large cysts, initial volumes 2700, 2000, and 
1752 ml, were exposed for only 10 minutes or less, the volumes were reduced to  212 ml, 0 
ml and 1 ml, a reduction in volumes of 92%, 100% and 100% after 18, 17 and 42 months 
respectively. Pain was severe in one patient and moderate in four others during or 
immediately following ethanol instillation. There were no other complications. There were no 
abnormalities in liver function tests following sclerotherapy. 
 
Paper II 
From March 1993 to November 1998, 23 cysts in 19 patients (18 female and one male) were 
treated by single-session ethanol sclerotherapy. Only patients with an observation period of a 
minimum of 12 months after single-session ethanol sclerotherapy were deemed eligible for 
the final analysis.  Eleven patients with eleven treated cysts fulfilled this criteria. After an 
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observation period of mean 38.3 (12 - 67) months, cyst volumes were reduced from mean 
1317 (200 - 2700) ml to mean 26 (0 - 188) ml, a volume reduction of mean 98 (93 -100)%. 
Thus, the post-sclerotherapy reaccumulation of fluid was followed by a significant volume 
reduction in 9 out of 10 patients. There were no complications.  
 
Paper III    
During the period from December 1996 to June 1999, 15 symptomatic liver cysts in nine 
patients (eight women and one man) were treated with a 10 minute exposure to ethanol. One 
70-year-old woman did not turn up for follow-up control examination, and the 4 cysts in her 
polycystic liver were therefore excluded. One cyst was excluded because the 83-year-old 
female patient died from cardiac disease 7 months after the procedure.  Only patients with an 
observation period of minimum 12 months after single-session ethanol sclerotherapy were 
found eligible for the final analysis. In 10 cysts in 7 patients with observation periods of 
median 23 (12-47) months, volumes were reduced from median 392 (30-4110) ml to median 
21.5 (0-523) ml, a reduction of the median cyst volume by 95%  (p < 0.005).  
The only complication was pain during the procedure. During cyst aspiration, pain was severe 
in two procedures and moderate in two. During ethanol instillation pain was severe in one 
procedure and moderate in two. After evacuation of all ethanol, irrigation with saline and 
removal of the catheter, one patient experienced moderate pain, while no patients experienced 
severe pain. Liver function tests and clinical follow-up did not reveal any sign of damage to 
biliary ducts or liver parenchyma. All patients experienced relief of their clinical symptoms. 
 
Paper IV 
During the period from September 1998 to November 1999 and during an additional period 
from May 2002 to September 2002, cystic fluid from 11 cysts in 11 patients was examined on 
the day of sclerotherapy, and again 2-8 days later(mean 4.5). The fluid was analyzed for 
cytologic and biochemical parameters. 
Biochemical parameters reflecting acute inflammatory reaction (C-reactive protein (CRP), 
haptoglobin and orosomucoid), cyst epithelial function (bilirubin and alkaline phosphatase), 
macromolecular leakage (protein and albumin), as well as parameters of hepatocyte function 
(alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) were significantly 
elevated following sclerotherapy.  
Cytologic signs of acute or subacute inflammatory reaction were absent before sclerotherapy, 
but present in all cysts after sclerotherapy. The number of cellular elements were increased in 
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all cysts and the relative percentages of different kinds of leucocytes could be calculated. In 
four cysts with an interval of two days between the first and the second sample 98-100% 
neutrophile granulocytes were present. In one cyst with an interval of two days and in all four 
cysts with an interval of six, seven or eight days the neutrophile granulocytes were partially 
replaced by lymphocytes and macrophages. In one cyst containing 100% lymphocytes before 
sclerotherapy, this was replaced by 98% neutrophile granulocytes and 2 % macrophages two 
days after sclerotherapy.  
In the last five patients an analysis of biochemical parameters in the blood was performed 
both before and following sclerotherapy. Before and after sclerotherapy the median CRP 
value in blood was 7 and 71 respectively. In the same patients the corresponding CRP values 
in cystic fluid before and after sclerotherapy was 9 (range 0-10) and 10 (range 5-24), 
respectively. The second blood sample was taken 2-3 days (mean 2.2) after sclerotherapy. The 
other parameters only demonstrated minor differences in the values before and following 
sclerotherapy. There were no complications. 
 
Paper V                                     
From 21 January 2000 to 11 November 2000, 1541 patients referred for an abdominal 
ultrasound examination were included. Liver cysts were diagnosed in 174 (11.3%). No cysts 
were found in patients younger than 40 years of age. The occurrence increased with age (p < 
0.0005). The occurrence in females was 12.5% (109/869) and in males 9.7% (65/672). This 
difference was not statistically significant (p = 0.088). The occurrence of liver cysts did not 
differ according to referring department (p = 0,559). Excluding 14 patients with polycystic 
liver disease (8.1% of 174 livers containing cysts and 0.9% of all livers), 322 cysts were 
recorded according to size in the remaining 160 patients: 91.9% with a diameter of 3 cm or 
less; 6.2% with a diameter between 3.1 and 6 cm; and 1.9% with a diameter greater than 6 
cm. Symptomatic cysts occurred in six patients, representing 0.4 % of all 1541 livers and 3.5 
% of all 174 livers containing cysts. These were all large cysts with a mean diameter of 115 
(60 - 180) mm. In examinations performed by senior radiologists cysts were diagnosed in 
16.1%, and in examinations performed by residents in 15.2% (p=0.785). 
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8. General discussion                                                     
Part I. Sclerotherapy of symptomatic liver cysts  
Study design.   
In principle, evaluation of new procedures and treatments ought to be performed using 
random controlled trials. However, in the present study the alternative standard treatment was 
surgery, a treatment associated with a higher morbidity and complication rate5;45. Based on 
ethical considerations and on earlier reported encouraging results on sclerotherapy, we felt 
that an observational trial offering sclerotherapy to patients in need of surgery was justified121. 
Moreover, the low prevalence of the disease would have made it difficult to accumulate 
enough patients for a random controlled trial5.  
Initially (Paper I and II), we examined the effect of single-session ethanol sclerotherapy using 
a time of exposure to ethanol of 20 minutes. Ethanol was left within the cyst for 10 minutes 
and then evacuated. A new dose of ethanol - the same volume – followed immediately, lasting 
for another 10 minutes, resulting in a total exposure to ethanol of 20 minutes. In three of the 
initial patients, ethanol was only injected once - for 7, 8 and 10 minutes, respectively, - 
because the patients experienced pain during the procedure. Although these cysts were large 
(2700ml, 2000ml and 1752 ml respectively) and the time of exposure was reduced, the 
sclerotherapy effect was still good, resulting in reductions of volume of 93%, 100% and 100 
% at follow-up observation after 41months, 53 months and 67 months, respectively (Table 1, 
Paper II). Due to this favourable result, we decided to conduct another study using a 10 
minute exposure to ethanol consecutively (Paper III). Ideally, the evaluation of 10 versus 20 
minutes exposure could have been performed using a random design. To the present, we have 
found no reports on the effect of different sclerotherapy methods using a random design. This 
in part reflects the difficulties in obtaining enough cases. Two reports on ethanol 
sclerotherapy of simple renal cysts compare single-session with multiple-session 
procedure122;123. In one paper, 82 cysts in 82 patients were reported. Forty-two cysts were 
treated by single-session and 40 by three different instillations of ethanol at 12 hour intervals. 
The mean follow-up periods were 12.9 and 15.4 months, respectively122. In another study, 19 
renal cysts in 15 patients were treated by single instillations of ethanol and 13 cysts in 11 
patients by repeated instillations of ethanol123. Both these studies concluded that the results 
were better when more than one session was used. Another author recommended the use of 
multiple sessions for renal cyst ethanol sclerotherapy123;124. In yet another study the long-term 
outcome of single-session sclerotherapy of 32 cysts in 32 patients was reported125. The mean 
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follow-up observation period was 55 months. The mean cyst diameter was 7.8cm before and 
1.7cm after sclerotherapy (p>0001). They concluded that single-session procedure of 
symptomatic renal cysts was efficient. 
 
In the present study, we only included patients with significant symptoms who were judged 
by the gastrointestinal surgeon to be in need of surgery. During the study period, all patients 
suffering from symptomatic liver cysts were included. No patient also surgically treated was 
included except for patient 2, Table III (see below). No patients withdrew from the study after 
having given their informed consent.  
 
Another limitation of the study was the deviation from the follow-up protocol. The frequency 
of follow-ups had been established at 3, 6 and 12 and 24 months. The intervals did vary, as 
illustrated in figures 1 in  Papers I, II and III. In spite of these variations, the scleroterapy 
effect could still be evaluated. In one patient in Paper II the first follow-up was made 24 
months after sclerotherapy. The volume reduction was 100 %, but since no examination was 
made at 3 or 6 months it was impossible to determine any presence or absence of a pattern of 
temporary post-procedural reaccumulation of fluid. Another patient included in Paper I was 
treated for a 4800ml cyst. She was seen at follow-up only once, at 7 months. By that time the 
volume of the cyst was reduced by 80%. Nevertheless, the surgeon operated on this patient 
one month later because her symptoms had not improved. After surgery her symptoms were 
unchanged. 
 
Pre and post-procedure measurements of cyst volume   
Accuracy of the method 
In the present study the cyst volume was estimated on the basis of the three maximal 
diameters (90° angles) measured on the CT images, according to the formula of an ellipsoid: 
Volume (V) = d1 x d2 x d3 x 0.523 120. This method has been used for the measurement of 
ovarian volume120, and the reported accuracy is good126. The method has also been used for 
the measurement of fetal urinary bladder volume for three decades127;128. Still others have 
estimated liver cyst volume 101;104and renal cyst volume125 by measuring one diameter .  
 
The effect on cyst volume  
The present studies showed that single-session ethanol sclerotherapy reduced cystic volume 
significantly over time. Our results support the initial observations of Kairaluoma, who in 
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1989 described that a single-session procedure was sufficient in spite of the refilling of the 
cyst after sclerotherapy, since the re-collected fluid was later resorbed. He claimed that this 
resorbtion and volume reduction lasted for more than one year102. Kairaluoma treated 15 cysts 
in eight patients. His first two patients were treated by a repeat sclerotheraphy procedure, the 
initial procedure being repeated after one or two months. He did observe that there was a 
temporary re-collection of fluid during the first two months after the initial sclerotheraphy 
procedure, but that the cyst thereafter decreased in size for at least two years. Due to this 
observation, he performed sclerotheraphy only once, with satisfactory results, on the 
following six patients. In our study, all patients of Papers I, II and III who had a follow-up 
examination during the first two months after sclerotherapy (16 out of 19 patients) had a re-
collection of fluid within the cyst (fig 1, Paper I, fig 1, Paper II and fig 1, Paper III). In all 
these patients this fluid was reduced in volume by 49-100% (median 95%) at later follow-ups. 
The post-sclerotherapy production of fluid within the cyst had also been observed by 
vanSonnenberg 32and Anderson83 in series of 14 and 9 patients, respectively. However, we 
believe that their observations led to an erroneous conclusion. They recommended that a 
percutaneous catheter be left in place until the next day, and that a repeated sclerotherapy 
procedure be performed if drainage was more than 10 – 15 ml per 24 hours. This resulted in a 
maximum time of drainage of 44 days (Table 2), as one single cyst was treated by 11 different 
sessions during 44 days of catheter drainage32. In our series, however, we showed that the 
long-term effect was excellent after one single sclerotherapy procedure when the catheter was 
removed immediately. There was a 99% reduction of cyst volume after seven to 67 months 
follow-up. Thus, our studies have shown that the post-sclerotherapy re-collection of fluid is 
temporary.  
 
Supplementary analysis: 
To examine the effect of sclerotherapy in regard to the duration of ethanol exposure, we 
carried out a retrospective analysis on the total study population included in Papers I-III 
(Table 3). A total of 19 patients (22 cysts) were studied, 17 women (89.4%) and 2 men (11.6 
%) with a median age of 61.2 (32.5-81.7) years. The median volume of cystic fluid was 680 
(30-4800) ml before and 6 (0-959) ml after sclerotherapy, a median volume reduction of 99.1 
% (p < 0,005). The median follow-up period was 30.8 (7.1 – 67.0) months.  
We divided the study population into those who had received an exposure of 10 minutes or 
less to ethanol (10 patients, 13 cysts) and those who had received an exposure of 20 minutes 
(9 patients, 9 cysts). For the group who had received 10 minutes or less of exposure, the 
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median pre-procedure cyst volumes was 840 ml (30-4110 ml) and the median post-procedure 
volume was 8 ml (0-470ml), a median volume reduction of 732 ml (99.1%) (p < 0.005). The 
median time of observation was 30.5 (13.1 – 67.0) months.  For the 9 patients (9 cysts) treated 
with 20 minutes exposure, the median volume was 680 ml (200-4800 ml) before and 0 ml (0-
959ml) after sclerotherapy, a median volume reduction of 680 ml (100%) (p < 0.005). The 
median time of observation was 30.0 (7.1 – 54) months. The degree of cyst reduction did not 
differ between the two groups (Mann- Whitney test for non-parametric data, p=0.896), 
confirming that 10 minutes of exposure is sufficient for the procedure to be successful.  
 
Clinical evaluation of symptoms 
In the present study, 26 out of a total of 28 patients reported that their symptoms had 
improved following sclerotherapy. Evaluation of symptoms was assessed by a gastrointestinal 
surgeon, who obtained a clinical statement on the condition of each patient (patient opinion) 
prior to the procedure. This was repeated at all the follow-up examinations at an outpatient 
clinical consultation 3, 6 and 12 months after treatment. Although specific methods of 
assessing pain and nausea have been developed to impose some structure on the information 
we were collecting, none of these were found to embrace the subjective symptom complexity 
of liver cysts, which includes different types of pain, early satiety, shortness of breath, 
reduced physical mobility and fitness, and psychological problems. Thus, we chose to 
evaluate the symptoms in their entirety, classifying them as the patients’ determination of 
improved, not changed or worsened. This may be seen to represent a weakness in the present 
study, but the examiner’s extensive experience in evaluating clinical symptoms related to liver 
disease should in part outweigh these shortcomings. Our results are supported by those of 
others 31;32;83;84;101;102;104. 
 
Evaluation of side effects.  
Procedural pain.   
Other than pain, there were no complications, a finding also reported by others 
31;32;83;84;101;102;104. In March 1994, during the second year of this study, 27 ml of ethanol was 
used to treat a 275 ml cyst (patient number 3, Table 3). When the catheter was removed after 
aspiration of ethanol, the patient experienced severe pain which lasted several days. We 
concluded that this may have been due to the leakage of ethanol into the peritoneal cavity. 
Even though it was considered that all ethanol was evacuated from the cyst before the catheter 
was removed, some ethanol may well have remained within the catheter. This would be 
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sufficient to create a localised chemical peritonitis. Due to this experience we changed our 
procedure. At the end of each procedure, when all ethanol had been evacuated, we irrigated 
the cyst with saline before removing the catheter. After this change of procedure, we have 
never had a similar experience as that described above.  
Also at the beginning of this study we observed that pain could be severe during cyst 
evacuation, before the application of ethanol, particularly in polycystic liver disease. We also 
observed that this pain during cyst evacuation was particularly severe in patients previously 
treated by liver surgery, and was probably the result of adhesions. This may well be similar to 
the experience of liver surgeons that laparoscopic fenestration of liver cysts is technically 
difficult if liver surgery has been done earlier, so that previous surgery is considered as a 
contra-indication for laparoscopic surgery120;129.  
As mentioned above, to improve pain control during the procedures, we reinforced the team 
with an anesthetic nurse who could provide the sedation and analgesics needed (Paper III). 
This improved pain control substantially, while still allowing the patient to change body 
position during the procedure.  
 
Ethanol intoxication 
Since ethanol intoxication was considered a potential side-effect, we examined our first 
patients (1993-1995, Paper I) for serum-ethanol one hour post-procedure. Because the values 
of ethanol observed were so low, the routine use of this test was discontinued (Paper I). Other 
authors have investigated the relationship between blood ethanol concentration, the volume of 
ethanol applied and the time of ethanol exposure. Kairaluoma et al found that the total volume 
of ethanol applied correlated significantly with the increase in blood ethanol content per 
kilogram body weight (p< 0.025, linear regression). Increased blood ethanol levels (maximum 
value 1.02 g/L) were measured by them in all eight patients treated for a total of 14 
cysts102.As compared to our procedure, Kairaluoma et al and Tikkakoski et al used 
significantly longer exposure time (60 minutes), as well as  higher volumes of ethanol31;102.  
 
Based on preliminary reports indicating a low risk for serious complications, and based on 
previous reports on the effect of ethanol on living cells, we chose ethanol as the sclerosing 
agent in the present study 130-134. Several series - involving large series of patients - have been 
published on the potential hepatotoxic effect of ethanol tumor ablation therapy 135;136. In a 
multicenter study the rate of serious complications associated with this therapy was reported 
to be 0.1%132. In another study there were no fatalities in 2485 procedures in 207 
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patients137.Some fatalities due to ethanol tumor ablation therapy have been noted 132;138;139. 
One 76-year-old man died from liver necrosis following percutaneous injection of 5 ml 
ethanol138, while doses per session as high as 200ml have been given with no reported 
fatalities140. In 333 high risk patients (large hepatocellular carcinoma, (HCC), liver cirrhosis) 
treated for hepatocellular carcinoma, there were 6 fatalities (1.8%): liver failure in one; 
rupture of HCC in one and rupture of esophageal varices in the remaining four141;142. 
However, so far no serious complications have been reported as a result of liver cyst ethanol 
sclerotherapy 31;32;83;84;101;102;104. While other sclerosing agents, such as minocycline, have 
been used in small series, the results are difficult to compare to ours115-117.  
 
Mechanism of sclerotherapy    
In in-vitro experiments the toxicity of ethanol upon living cells is dependent upon the duration 
of exposure to ethanol and upon the concentration of ethanol130. In animal experiments the 
effect of ethanol upon liver tissue has been investigated 131;143. Okano evaluated the 
sclerotherapeutic effect of different concentrations of ethanol in patients, concluding that a 
concentration below 40% is inefficient 144.  
In Paper IV we studied the mechanism of ethanol liver cyst sclerotherapy, evaluated by 
cytologic and biochemical parameters before and after sclerotherapy. Cytologic signs of acute 
or subacute inflammatory reaction were absent in the fluid from all cysts before sclerotherapy 
and present in the fluid from all cysts following sclerotherapy. The biochemical parameters of 
acute inflammatory reaction CRP, orosomucoid and haptoglobine were significantly elevated 
in cystic fluid after sclerotherapy.  
The same parameters were examined both in blood and in cystic fluid in only the last five 
patients included in Paper IV. In these patients there was a discrepancy between blood and 
cystic fluid as regards the most important biochemical parameter, CRP, the main indicator of 
acute inflammation. In blood, the median value of CRP was normal before sclerotherapy and 
significantly elevated after the procedure. In cystic fluid, CRP was only slightly elevated 
either before or after the procedure. A possible explanation for this could be that cystic fluid is 
avascular, whereas the CRP elevation in blood reflects the inflammatory reaction in the 
vascularised cystic wall. Of importance was also the observation that there were no signs of 
liver tissue damage found in blood when tested for ALT and AST values, nor were these 
values high in postsclerotherapy cystic fluid. This accords well with our experience that 
ethanol liver cyst sclerotherapy is a method of low risk, causing little or no damage to liver 
tissue. The re-collection of cystic fluid after sclerotherapy is probably due to macromolecular 
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leakage through increased gaps that occur between the endothelial cells in capillaries and 
venules. This agrees with the increase of protein and albumin concentration found in cystic 
contents following sclerotherapy. The significant differences in cystic fluid between pre- and 
post-sclerotherapy values of alkaline phosphatase and bilirubin might support the theory that 
there is a devitalisation of cystic epithelium when exposed to ethanol. Bilirubin and ALP may 
well leak from the adjacent liver tissue into the cystic cavity, due to ethanol damage of the 
cystic wall. We have not been able to find similar studies from other authors for the 
comparison of results. 
 
The fact that fluid reaccumulates within the cyst after sclerotherapy and then not only is 
gradually resorbed but never reappears strongly indicates that this fluid is the product of a 
temporary inflammatory reaction in the cystic wall which has lost remaining vital epithelium.  
 
ALT is the main biochemical indicator of liver cell function. The slight elevation of ALT 
indicates that the ethanol-induced damage has not only affected the cyst epithelium but also 
the adjacent liver tissue. This minor liver tissue damage is of no clinical significance. Severe 
liver tissue damage as a complication of ethanol liver cyst sclerotherapy has not been reported 
in the literature.  
 
A control group, where cytologic and biochemical tests were taken both before and after 
catheterization of the liver cysts - without the use of ethanol  - would have been desirable but 
was not attempted for ethical as well as practical reasons.   
 
Part II. Occurrence of liver cysts. 
Study design 
The aim of this prospective, cross-sectional study was to evaluate the occurrence of liver cysts 
in our population, using high-resolution ultrasonography. To do so, we examined 1541 
patients referred for an ultrasound examination at our hospital during the year 2000. In order 
to reduce the possibility of sampling bias, we used a large sample size over a study period of 
one year. We closely examined the data for inconsistentcies due to sex, age and referring 
department. The data was also evaluated to determine varience due to different examiners.  
All examinations were performed by one of 24 radiologists or radiology residents in a daily 
practice setting, and the patients were consecutively registered except for those days or 
periods when none of the 24 participating radiologists were present at the ultrasound 
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laborotory. Such periods occurred randomly throughout the study period. The data was well 
arranged with regard to age, sex and referring department, and the diagnosis of liver cysts did 
not differ significantly between radiologists and radiology residents. We therefore believe that 
we can make valid generalizations based upon our hospital-based sample. In accordance with 
guidelines from the Regional Ethics Committee, no informed consent was judged necessary 
for this clinical evaluation, since all data were made anonymous prior to analysis.  
 
Accuracy of the results  
The accuracy of ultrasonography in the detection of liver cysts is influenced by several factors 
related to the patient, to the ultrasound machine and technique used, and to the examiner. A 
restricted ultrasound view related to obesity, small-sized liver positioned far cranially in 
combination with bowel tympanism, an uncooperative patient and/or recent abdominal 
operation all tend to decrease the sensitivity. However, these factors may in part be 
outweighted by the correct positioning of the patients.  
 
Image resolution depends on technical factors such as focusing145, advanced computerised 
organisation of emission and receiver functions, emission frequency and post-processing 
capabilities. Even though we used high-resolution machines, they were probably insufficient 
in diagnosing cysts of 5 - 10 mm diameter at 4-10 cm depth except in lean, small-size patients 
optimally suited for US examination.  Thus, our results are likely to underestimate the 
occurence of very small liver cysts.  
 
We found no statistically significant differences between radiology consultants and residents 
in the number of liver cysts detected, suggesting that reporting done by these two groups is 
consistent.  
The occurrence of liver cysts.    
In our hospital-based population we found that 11.3% of the patients had at least one liver 
cyst. In previous ultrasound studies of a similar design, the occurrence of hepatic cysts has 
varied  between 2.5% during the period 1855-87 27, to 4.7% during the period 1990-92 25. 
These differences could be due to differences in the ultrasound machines used, to the 
experience of the examiners, or to true differences among populations.  
 
In accordance with other authors27 we did not find any significant differences in the 
occurrence of liver cysts according to sex. Some authors have reported on a female 
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dominance as regards symptomatic liver cysts31;32; however, we did not see this. In 1974 
Sanfelippo 30 reported on an occurrence of symptomatic liver cysts of 0.02% (15 in 88 000 
explorative laparatomies). At that time, imaging technology was far less developed than 
presently , so Sanfelippo may well have underestimated the occurrence of non-symptomatic 
hepatic cysts; however, the rate of  symptomatic liver cysts seems quite realistic.  
 
The increasing occurrence of liver cysts with age was highly significant. The absence of cysts 
in individuals below the age of 40 is likewise highly significant. This observation is of great 
importance in tumor staging in young patients suffering from malignant disease. Regardless 
of the patients’ age and regardless of the imaging modality applied, the diagnosis of cysts is 
uncertain when the diameter of the lesion is less than 10 mm. because of the averaging effect. 
If, for instance, a 5 mm lesion is found in the liver of a 30-year-old cancer patient, and it is 
impossible to decide by imaging methods whether this is a cyst or a solid lesion, statistically 
this is more likely to be a metastasis, whereas in an 80-year-old patient this lesion is 
statistically more likely to represent a cyst.  
It is important, when staging cancer patients, to know if there is a correlation between the 
occurrence of liver cysts and the presence of malignant disease. No statistically significant 
correlation was found between the occurrence of liver cysts and the presence or absence of 
malignant disease. This finding is based upon the occurence of liver cysts in Departments 
with both a high and a low occurrence of malignant disease. Only with regard to the Pediatric 
Department there was a difference in the occurrence of liver cysts compared to other 
Departments; cysts were completely abscent in all children examined. This statistically 
significant difference is correlated to age and not to the presence or absence of malignant 
disease.  
We found no differences between residents and senior radiologists in the detection rate of 
cysts. The high number of examiners with different levels of experience did not appear to 
have biased our results.  
 
In his study, Gaines27 excluded patients suffering from polycystic liver disease, whereas 
Carimani25 included them. However, the conclusion for either of these studies as regards the 
occurrence of liver cysts would have been unchanged, since polycystic livers represent such a 
small proportion of the patients. All polycystic livers included in the present study fulfilled 
the criteria of more than 10 cysts as given by Ros3,  who in turn refers to Bosniak146.  
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Symptomatic cysts occurred in 3.5% of livers containing cysts. This is a high figure compared 
to the results of Sanfelippo (2 symptomatic cyst per 10 000 laparatomies, an occurrence of 
0.02%). The number of patients treated for symptomatic liver cysts per year during the period 
1993 – 2005 residing in the County of Hordaland was 0-5 patients (mean 3.1), i.e. 1 per  
145 566 inhabitants per year (0.0007%). This corresponds better with the results of 
Sanfelippo. 
 
9. Conclusions    
1. Single-session ethanol sclerotherapy results in a significant reduction of cyst volume in 
benign, symptomatic liver cysts. 
2. Following ethanol sclerotherapy a re-accumulation of fluid within the cyst is observed. 
This re-accumulation of fluid is temporary. 
3. Neither repeated sclerotherapy procedures nor prolonged periods of catheter drainage are 
necessary. 
4. Long term follow-up demonstrated that ethanol sclerotherapy not only has a temporarily 
palliative effect, but also results in long-lasting significant cyst volume reduction. 
5. Our initial results indicate that it is possible to simplify the method of ethanol liver cyst 
sclerotherapy by reducing the time of exposure to ethanol from 20 to 10 minutes, thus 
reducing the volume of ethanol used. 
6. Our results support the hypothesis that the post-sclerotherapy temporary re-accumulation 
of fluid within the cyst is the result of an inflammatory reaction.  
7. The reduction in cyst volume achieved by sclerotherapy leads to an improvement in the 
patients’ symptoms. 
8. The occurrence of liver cysts in a hospital-based population is higher than reported in 
previous studies. 
9. Symptomatic cysts occurred in 3.5% of livers containing cysts in our hospital patient 
population. 
 
10. Future aspects 
At our institution we now have treated 132 cyst in 60 patients. Twenty-five of these patients 
were suffering from polycystic liver disease. In some of these patients more than 10 cysts 
have been treated by ethanol sclerotherapy. Among these patients were candidates for liver 
transplantation. Preliminary results might indicate that in selected patients ethanol 
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sclerotherapy of multiple cysts might not only replace fenestration and liver resection, but 
even liver transplantation as the method of choice. We want to participate in further research 
in order to clarify this topic. 
Paper III deals with the initial results of sclerotherapy performed with a short time of 
exposure to ethanol. Since 1999 we have continued this investigation by consecutively 
performing sclerotherapy with a reduced time of exposure to ethanol. We want to continue 
our research aiming at further simplification and standardisation of the method of ethanol 
sclerotherapy. 
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